RxDoctor Payments Data

Tara McCabe

Family · New Brunswick, NJNPI 1972962504

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Seagen Inc. accounts for 87.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $16,975 and has fallen 91.6% since, to $1,419 in 2025. Among family clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,309in general payments, 2019–2025

Across 74 payments — averaging $301.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$19K
  • Pfizer$1K
  • Genmab U.S., Inc.$980
  • Incyte Corporation$116
  • Jazz Pharmaceuticals Inc.$76
  • Astellas Pharma US Inc$74
  • plus $208 from 7 others

What the payments were for

  • Consulting fees$5,57025%
  • Speaking & faculty fees$11,01049%
  • Travel & lodging$3,81317%
  • Food & beverage$1,5657%
  • Education$3512%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,309 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$32,367
Medicare patients
84
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate15$174,084
EliquisApixaban16$8,976
Acyclovir178$2,592
Entecavir14$916
Fluconazole18$760
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim98$446
Pantoprazole Sodium23$229
Gabapentin21$195
Prednisone43$126
Ondansetron Hcl20$124
Allopurinol27$122
Levofloxacin15$85
Alprazolam11$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$50$174,08415 claims
PfizerEliquis$1,387$8,97616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.

Other family in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →